Diagnostic performance of GPT-4 in analyzing radiology findings from brain tumors

FHS
October 3, 2024
11:52 am

GPT-4 demonstrates diagnostic capabilities in brain radiology, achieving 73% accuracy for final diagnoses and 94% for differential diagnoses in recent research.

Syndax wins U.S. approval for leukemia treatment

The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a genetically defined form of advanced

November 18, 2024

Teladoc names insurance executive as new CEO

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 11, 2024

CureVac Doses First Patient in Phase 1 Study of Cancer Vaccine Candidate for Surgically Resected Glioblastoma – Biotech Investments

Issuer: CureVac / Key word(s): Study 20.06.2023 / 13:05 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac Doses First Patient

June 21, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.